Protein / target

Angiopoietin-2

ANGPT2O15123Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
30
Clinical trials
Antibody-tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Receptor tyrosine kinase binding

Primary system

Cardiovascular system

Strongest disease association

lymphatic malformation 10

Genetic literature evidence · score 0.83

Therapeutic maturity

Clinically validated target

1 approved medicine against this target

Druggability

Antibody

Open Targets tractability · Approved Drug

Clinical development

1 approved · 7 in clinical development

30 linked trials

Research activity

Emerging research

2 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1 (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Involved in the regulation of lymphangiogenesis (PubMed:32908006)

Subcellular location

Secreted
Domains and Gene Ontology detail (27)

Domains & features

Fibrinogen C-terminal

Gene Ontology

  • Ccell projection
  • Cextracellular matrix
  • Cextracellular region
  • Cextracellular space
  • Fmetal ion binding
  • Freceptor ligand activity
  • Freceptor tyrosine kinase binding
  • Fsignaling receptor binding
  • Pangiogenesis
  • Panimal organ regeneration
  • Pblood coagulation
  • Pcellular response to growth factor stimulus

496 aa · 57 kDa · 3 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Kinase signallingUniProtCell adhesionGOTranscriptional regulationGOHaemostasisGO
View supporting evidence

Kinase signalling

  • ·Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signalin…

Cell adhesion

  • ·extracellular matrix

Transcriptional regulation

  • ·gene expression

Haemostasis

  • ·blood coagulation
View underlying pathways (1)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

TEKTIE1NTRK1KDRFLT1FLT4ANGPT4ANGPT1IGHV3-…VWFANGPT2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

faricimab
Narrow target profileApprovedInhibitor

Angiopoietin-2 inhibitor

Appears in clinical studies involving diabetic macular edema, wet macular degeneration, macular retinal edema, wet macular degeneration

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

lymphatic malformation 100.83

Genetic literature · overall 0.62

microcephaly 1, primary, autosomal recessive0.79

Genetic · overall 0.48

hemorrhoid0.67

Genetic · overall 0.41

open-angle glaucoma0.61

Genetic · overall 0.38

hydrops fetalis0.61

Genetic literature · overall 0.39

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

wet macular degeneration0.92

Clinical · overall 0.57

diabetic macular edema0.92

Clinical · overall 0.56

macular retinal edema0.76

Clinical · overall 0.47

ovarian carcinoma0.59

Clinical · overall 0.38

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

Non-immune hydrops fetalis0.38

Genetic

Show all associations
lymphatic malformation 100.62
wet macular degeneration0.57
diabetic macular edema0.56
microcephaly 1, primary, autosomal recessive0.48
macular retinal edema0.47
hemorrhoid0.41
hydrops fetalis0.39
Non-immune hydrops fetalis0.38
ovarian carcinoma0.38
open-angle glaucoma0.38

Open Targets ranks 1,013 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 8 total

NESVACUMABPhase 2

diabetic macular edema · age-related macular degeneration · age-related macular degeneration

TREBANANIBPhase 3

breast cancer · neuropathic pain · ovarian cancer

MEDI-3617Phase 1

ovarian cancer · melanoma

AMG-780Phase 1
CVX-060Phase 2

renal cell carcinoma · glioblastoma

ZANSECIMABPhase 2

COVID-19 · pneumonia · COVID-19

FARICIMABApproval

diabetic macular edema · wet macular degeneration · macular retinal edema

VANUCIZUMABPhase 2

colorectal cancer · metastatic colorectal cancer · hepatocellular carcinoma

Tractability

AB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMOC · Advanced Clinical

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

ClinicalTrials.gov via the drug-target graph.

Research activity

2 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

microcephaly 1, primary, autosomal recessiveWell supported
0.79
agreement 0.670.91
Genetic100%

Open Targets aggregate 0.48 · 1 independent evidence family

lymphatic malformation 10Moderately supported
0.72
agreement 0.600.84
Genetic100%Genetic literaturedup

Open Targets aggregate 0.62 · 1 independent evidence family · 1 not counted as duplicate

wet macular degenerationModerately supported
0.70
agreement 0.540.85
Clinical97%Literature3%

Open Targets aggregate 0.57 · 2 independent evidence families

diabetic macular edemaModerately supported
0.69
agreement 0.540.85
Clinical98%Literature2%

Open Targets aggregate 0.56 · 2 independent evidence families

hemorrhoidModerately supported
0.67
agreement 0.550.79
Genetic100%

Open Targets aggregate 0.41 · 1 independent evidence family

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

5

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Clinical trial activity2026-06-23
    Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet

    Fierce Biotech · news · via faricimab

  2. New publication2026-02-26
    Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.

    Ophthalmology science · 2026 · Europe PMC · via faricimab

  3. New publication2026-01-12
    Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.

    Ophthalmology · 2026 · 1 citation · Europe PMC · via faricimab

  4. Regulatory approval2022-09-15

    Approval: Vabysmo (EMA)

    ema · regulatory · ema · via faricimab

  5. New publication2022-01-24
    Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

    Lancet (London, England) · 2022 · 578 citations · Europe PMC · via faricimab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.